http://www.sciencedaily.com/news/health_medicine/prostate_cancer/ Learn the symptoms of prostate cancer. Read current medical research on new treatment options, vaccines, surgery and prevention. en-us Thu, 12 Nov 2009 09:05:02 EST Thu, 12 Nov 2009 09:05:02 EST 60 http://www.sciencedaily.com/images/logosmall.gif http://www.sciencedaily.com/news/health_medicine/prostate_cancer/ For more science articles, visit ScienceDaily. http://www.sciencedaily.com/releases/2009/11/091104140822.htm Researchers have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival. Wed, 11 Nov 2009 20:00:00 EST http://www.sciencedaily.com/releases/2009/11/091104140822.htm http://www.sciencedaily.com/releases/2009/11/091103144814.htm Hypofractionated radiation treatment, a newer type of radiation treatment that delivers higher doses of radiation in fewer treatments than conventional radiation therapy, is significantly more effective in stopping cancer from growing in high risk patients, compared to receiving standard radiation treatment, according to a new study. In addition, findings show there is no increased risk of negative side effects later in patients who undergo hypofractionated radiation. Tue, 10 Nov 2009 23:00:00 EST http://www.sciencedaily.com/releases/2009/11/091103144814.htm http://www.sciencedaily.com/releases/2009/11/091110112442.htm New research studied the association between prostate-specific antigen levels and prostate size and found that routine annual evaluation of prostate growth is not necessarily a predictor for the development of prostate cancer. However, the study suggests that if a man's PSA level is rising quickly, a prostate biopsy is reasonable to determine if he has prostate cancer. Tue, 10 Nov 2009 00:00:00 EST http://www.sciencedaily.com/releases/2009/11/091110112442.htm http://www.sciencedaily.com/releases/2009/11/091104152255.htm Men whose prostate specific antigen rise within 18 months of radiotherapy are more likely to develop spread and die of their disease, according to an international study. Mon, 09 Nov 2009 11:00:00 EST http://www.sciencedaily.com/releases/2009/11/091104152255.htm http://www.sciencedaily.com/releases/2009/11/091105165527.htm Researchers have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings could lead to novel therapeutic approaches for these diseases. Sun, 08 Nov 2009 05:00:00 EST http://www.sciencedaily.com/releases/2009/11/091105165527.htm http://www.sciencedaily.com/releases/2009/11/091103121607.htm Men with lower cholesterol are less likely than those with higher levels to develop high-grade prostate cancer -- an aggressive form of the disease with a poorer prognosis, according to results of a new study. Fri, 06 Nov 2009 14:00:00 EST http://www.sciencedaily.com/releases/2009/11/091103121607.htm http://www.sciencedaily.com/releases/2009/11/091106145415.htm Researchers have discovered that some elevated prostate-specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy. Fri, 06 Nov 2009 00:00:00 EST http://www.sciencedaily.com/releases/2009/11/091106145415.htm http://www.sciencedaily.com/releases/2009/11/091104122517.htm A patient's socioeconomic status (income, martial status and race) has absolutely no impact on his outcome following curative radiation therapy for the treatment of prostate cancer, according to a new study. It is unique in that nearly 50 percent of patients in the analysis are African-American. Thu, 05 Nov 2009 17:00:00 EST http://www.sciencedaily.com/releases/2009/11/091104122517.htm http://www.sciencedaily.com/releases/2009/11/091103171917.htm A study of 572 men with localized prostate cancer suggests that size and shape of tumor blood vessels may predict whether the tumor will grow aggressively and require immediate treatment or grow slowly and allow therapy and its risks to be safely delayed. Aggressive prostate tumors tend to have blood vessels that are small, irregular and primitive in cross-section, while slow-growing or indolent tumors have blood vessels that look more normal. Wed, 04 Nov 2009 08:00:00 EST http://www.sciencedaily.com/releases/2009/11/091103171917.htm http://www.sciencedaily.com/releases/2009/11/091103144816.htm A shorter, five-week course of radiation treatment that delivers higher doses of radiation in fewer sessions, known as hypofractionation, appears to be just as effective and as safe in reducing the risk of prostate cancer from returning as standard radiation therapy, yet is delivered in two-and-a-half weeks less time, according to interim results of a randomized study. Tue, 03 Nov 2009 00:00:00 EST http://www.sciencedaily.com/releases/2009/11/091103144816.htm http://www.sciencedaily.com/releases/2009/11/091103121559.htm A pair of studies lay to rest the decades-long concern that lower total cholesterol may lead to cancer, and in fact lower cholesterol may reduce the risk of high-grade prostate cancer. Tue, 03 Nov 2009 00:00:00 EST http://www.sciencedaily.com/releases/2009/11/091103121559.htm http://www.sciencedaily.com/releases/2009/11/091102171425.htm Proton beam therapy can be safely delivered to men with prostate cancer and has minimal urinary and rectal side effects, according to a new study. Mon, 02 Nov 2009 23:00:00 EST http://www.sciencedaily.com/releases/2009/11/091102171425.htm http://www.sciencedaily.com/releases/2009/11/091102111837.htm Researchers report that radiation therapy alone can reduce prostate specific antigen (PSA) levels below detectable amounts in prostate cancer patients. Patients who have an undetectable level of PSA after therapy have less chance of biochemical failure than other patients and a good chance of being cured. Mon, 02 Nov 2009 17:00:00 EST http://www.sciencedaily.com/releases/2009/11/091102111837.htm http://www.sciencedaily.com/releases/2009/11/091102121641.htm Short-term hormone therapy given prior to and during intermediate dose radiation treatment for men with early stage prostate cancer increases their chance of living longer, compared to those who receive the same radiation alone, according to a new study. Mon, 02 Nov 2009 00:00:00 EST http://www.sciencedaily.com/releases/2009/11/091102121641.htm http://www.sciencedaily.com/releases/2009/11/091102121502.htm Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer prostate cancer recurrences compared to men who did not receive the extra dose of proton radiation. Mon, 02 Nov 2009 00:00:00 EST http://www.sciencedaily.com/releases/2009/11/091102121502.htm http://www.sciencedaily.com/releases/2009/10/091029141219.htm Researchers have discovered what leads to two genes fusing together, a phenomenon that has been shown to cause prostate cancer to develop. Fri, 30 Oct 2009 05:00:00 EDT http://www.sciencedaily.com/releases/2009/10/091029141219.htm http://www.sciencedaily.com/releases/2009/08/090827123212.htm Researchers have modified siRNA, a type of genetic material that can block potentially harmful activity in cells, so that it can be injected into the bloodstream and impact targeted cells while producing fewer side effects. The findings could make it easier to create large amounts of targeted therapeutic siRNAs for treating cancer and other diseases. Thu, 22 Oct 2009 17:00:00 EDT http://www.sciencedaily.com/releases/2009/08/090827123212.htm http://www.sciencedaily.com/releases/2009/10/091020181301.htm Twenty years of screening for breast and prostate cancer -- the most diagnosed cancer for women and men -- have not brought the anticipated decline in deaths from these diseases, argue experts in an opinion piece. Thu, 22 Oct 2009 08:00:00 EDT http://www.sciencedaily.com/releases/2009/10/091020181301.htm http://www.sciencedaily.com/releases/2009/10/091019162927.htm Researchers, using an extremely sensitive tool based on nanotechnology, have detected previously undetectable levels of prostate-specific antigen (PSA) in patients who have undergone radical prostatectomy. With technology 300 times more sensitive than commercially available PSA tests, the researchers found measureable PSA levels in each post-operative patient in its study. After the removal of the prostate gland, patients typically have PSA levels that are undetectable when measured using conventional diagnostic tools. Tue, 20 Oct 2009 11:00:00 EDT http://www.sciencedaily.com/releases/2009/10/091019162927.htm http://www.sciencedaily.com/releases/2009/10/091015191701.htm The xenotropic murine leukemia virus-related virus which has previously been linked to prostate cancer has been found to have a dramatically lower prevalence among German prostate cancer patients, if any. Contrary to some reports, which have found XMRV in 40 percent of cases in patients in the US with familial prostate cancer, new research has found no link between the two conditions in a large study of German prostate cancer patients. Tue, 20 Oct 2009 02:00:00 EDT http://www.sciencedaily.com/releases/2009/10/091015191701.htm http://www.sciencedaily.com/releases/2009/10/091010120725.htm Researchers have found that urokine plasminogen activator (uPA) may be instrumental in the early stages of metastasis. Prostate cancer, which develops most frequently in men over fifty, is the most common type of cancer of men in the United States. Most prostate cancer-related deaths are due to advanced disease, which often results in metastatic spread to other organs. Sat, 10 Oct 2009 00:00:00 EDT http://www.sciencedaily.com/releases/2009/10/091010120725.htm http://www.sciencedaily.com/releases/2009/10/091008113318.htm Clinical researchers can now answer the question that baffles many clinicians -- why do some men with elevated prostate specific antigen levels who are carefully monitored and undergo repeated negative biopsies still develop aggressive prostate cancer? Thu, 08 Oct 2009 20:00:00 EDT http://www.sciencedaily.com/releases/2009/10/091008113318.htm http://www.sciencedaily.com/releases/2009/10/091005161439.htm A new drug designed to "seek and destroy" common cancers is being tested. The Phase I clinical trial is designed to evaluate the safety of EP-100 in adult patients with solid tumors whose tumor biopsies indicate that they have excessive LHRH receptors. Excessive LHRH receptors are found in a wide range of cancers, including breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers. Tue, 06 Oct 2009 20:00:00 EDT http://www.sciencedaily.com/releases/2009/10/091005161439.htm http://www.sciencedaily.com/releases/2009/09/090928131212.htm The largest single-institution study of its kind has found few complications in prostate cancer patients treated with radiotherapy after surgery to remove the prostate. Men in this study received radiotherapy after a prostate-specific antigen test following surgery indicated their cancer had recurred. Tue, 29 Sep 2009 08:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090928131212.htm http://www.sciencedaily.com/releases/2009/09/090927130034.htm Researchers believe that androgen deficiency might be the underlying cause for a variety of common clinical conditions, including diabetes, erectile dysfunction, metabolic syndrome and cardiovascular disease. Mon, 28 Sep 2009 05:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090927130034.htm http://www.sciencedaily.com/releases/2009/09/090928172346.htm Men largely make decisions about prostate cancer screening based on conversations with their clinicians, but these discussions often do not include information about the risks of testing in addition to the benefits, according to a new report. A second report uses statistical modeling to estimate the benefits and risks of prostate-specific antigen screening in men of various ages and risk levels. Mon, 28 Sep 2009 00:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090928172346.htm http://www.sciencedaily.com/releases/2009/09/090928095208.htm A Swiss study finds prostate cancer patients of low socioeconomic status are more likely to die than patients with higher incomes. Mon, 28 Sep 2009 00:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090928095208.htm http://www.sciencedaily.com/releases/2009/09/090923102335.htm Research involving more than 500 prostate cancer patients has revealed two thirds of cases did not require urgent treatment, due to the absence of a protein that indicates progressive disease. Thu, 24 Sep 2009 23:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090923102335.htm http://www.sciencedaily.com/releases/2009/09/090923102402.htm Immune therapies have been explored as a way to treat cancer after it develops. But a new study suggests that genetic risk of prostate cancer can be reduced by rescuing critical immune system cells. Thu, 24 Sep 2009 02:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090923102402.htm http://www.sciencedaily.com/releases/2009/09/090922095653.htm New research has found that hormone therapy used to treat men with advanced prostate cancer is associated with an increased chance of developing various heart problems. Some choices of therapy appear, however, to be less risky than others. Wed, 23 Sep 2009 05:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090922095653.htm http://www.sciencedaily.com/releases/2009/09/090915101145.htm Report finds Hispanic/Latino Americans are less likely than non-Hispanic whites to develop and die from all cancers combined as well as the four most common cancers, but have higher rates of several cancers related to infections and are more likely to have cancer detected at a later stage. Wed, 16 Sep 2009 11:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090915101145.htm http://www.sciencedaily.com/releases/2009/09/090915174321.htm A comparison of outcomes of different eras of conservative treatment for localized prostate cancer indicates that overall and prostate cancer-specific survival rates are higher for men diagnosed from 1992 through 2002 compared to men diagnosed in the 1970s and 1980s, according to a new study. Tue, 15 Sep 2009 00:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090915174321.htm http://www.sciencedaily.com/releases/2009/08/090831212956.htm Appropriately selected prostate cancer patients, including older men and men with small, low-risk tumors, may safely defer treatment for many years with no adverse consequences, according to a new study. Mon, 14 Sep 2009 11:00:00 EDT http://www.sciencedaily.com/releases/2009/08/090831212956.htm http://www.sciencedaily.com/releases/2009/08/090831212444.htm The introduction of prostate-antigen screening, or PSA, has resulted in over one million additional men over the last 23 years being diagnosed and treated for prostate cancer -- most of whom were likely overdiagnosed, researchers reported in a new study. Mon, 14 Sep 2009 08:00:00 EDT http://www.sciencedaily.com/releases/2009/08/090831212444.htm http://www.sciencedaily.com/releases/2009/09/090909162926.htm A new study has found a strong association between the common sexually transmitted infection, Trichomonas vaginalis, and risk of advanced and lethal prostate cancer in men. Thu, 10 Sep 2009 14:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090909162926.htm http://www.sciencedaily.com/releases/2009/09/090909133024.htm A new type of stem cell discovered in the prostate of adult mice can be a source of prostate cancer, according to a new study. Thu, 10 Sep 2009 11:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090909133024.htm http://www.sciencedaily.com/releases/2009/09/090907162310.htm In a finding with potentially major implications for identifying a viral cause of prostate cancer, researchers have reported that a type of virus known to cause leukemia and sarcomas in animals has been found for the first time in malignant human prostate cancer cells. Tue, 08 Sep 2009 05:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090907162310.htm http://www.sciencedaily.com/releases/2009/08/090811143533.htm Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer, a study has found. Mon, 07 Sep 2009 20:00:00 EDT http://www.sciencedaily.com/releases/2009/08/090811143533.htm http://www.sciencedaily.com/releases/2009/09/090902151119.htm Moderately to severely obese prostate cancer patients may have improved treatment outcomes when treated with image-guided radiation therapy (IGRT) over traditional external beam radiation therapy (EBRT) because IGRT corrects for prostate shifts, which, if not planned for, can lead to incorrect doses of radiation to the disease site, according to a new study. Thu, 03 Sep 2009 23:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090902151119.htm http://www.sciencedaily.com/releases/2009/09/090901150955.htm A new study shows that positron emission tomography (PET)/computer tomography (CT) scans with the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed. Wed, 02 Sep 2009 20:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090901150955.htm http://www.sciencedaily.com/releases/2009/09/090901132802.htm Body mass in younger and older adulthood, and weight gain between these periods of life, may influence a man's risk for prostate cancer. This risk varies among different ethnic populations, according to results of a new study. Wed, 02 Sep 2009 11:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090901132802.htm http://www.sciencedaily.com/releases/2009/09/090902161114.htm A third of the previously identified single-nucleotide polymorphisms, or SNPs, associated with prostate cancer in men of European or African ancestry were also associated with prostate cancer in a Japanese population, according to a new study. Wed, 02 Sep 2009 00:00:00 EDT http://www.sciencedaily.com/releases/2009/09/090902161114.htm http://www.sciencedaily.com/releases/2009/08/090826110116.htm Researchers have demonstrated that the protein Brk plays a role in breast cancer progression and dissemination. Sat, 29 Aug 2009 11:00:00 EDT http://www.sciencedaily.com/releases/2009/08/090826110116.htm http://www.sciencedaily.com/releases/2009/08/090825163722.htm Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to a new study. Wed, 26 Aug 2009 23:00:00 EDT http://www.sciencedaily.com/releases/2009/08/090825163722.htm http://www.sciencedaily.com/releases/2009/08/090821163511.htm Elevated insulin levels in the normal range appear to be associated with an increased risk of prostate cancer, according to a new study. Sun, 23 Aug 2009 17:00:00 EDT http://www.sciencedaily.com/releases/2009/08/090821163511.htm http://www.sciencedaily.com/releases/2009/08/090818150016.htm Patients who experience fatigue during radiotherapy for breast or prostate cancer may be reacting to activation of the proinflammatory cytokine network, a known inflammatory pathway, according to new research. Thu, 20 Aug 2009 20:00:00 EDT http://www.sciencedaily.com/releases/2009/08/090818150016.htm http://www.sciencedaily.com/releases/2009/08/090819123939.htm Researchers have destroyed prostate cancer tumors in mice by injecting them with specially-coated, minuscule carbon tubes and then superheating the tubes with a brief zap of a laser. Thu, 20 Aug 2009 14:00:00 EDT http://www.sciencedaily.com/releases/2009/08/090819123939.htm http://www.sciencedaily.com/releases/2009/08/090814165259.htm Researchers have identified a novel genetic mechanism that may govern an individual's risk of developing prostate cancer. Tue, 18 Aug 2009 23:00:00 EDT http://www.sciencedaily.com/releases/2009/08/090814165259.htm